Sanofi and Altrad both bring four and seven year combos
◆ Investors offered identical deals at each end of the rating spectrum ◆ Sanofi appears to come flat to fair value ◆ Both get more demand for seven year tranches
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: